Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Balsm Alofoq Medical CoSAU:9620 24 Altman Z2-Score is 11.27 as of Aug. 06, 2026, which is at its 10-year median of 11.27. GuruFocus rates SAU:9620 with a GF Score™ of 24/100. The stock has 4 warning signs investors should review. Among 841 Medical Devices & Instruments companies, Balsm Alofoq Medical Co ranks better than 87.04% on this metric.
Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.
Good Sign:
Balsm Alofoq Medical Co has a Altman Z2-Score of 11.27, indicating it is in Safe Zones. This implies the Altman Z2-Score is strong.
The zones of discrimination were as such:
When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.
The historical rank and industry rank for Balsm Alofoq Medical Co's Altman Z2-Score or its related term are showing as below:
SAU:9620'
s Altman Z2-Score Range Over the Past 10 Years
Min: 7.32 Med: 11.27 Max: 12.48
Current: 11.27
During the past 3 years, Balsm Alofoq Medical Co's highest Altman Z2-Score was 12.48. The lowest was 7.32. And the median was 11.27.
Balsm Alofoq Medical Co (SAU:9620) Altman Z2-Score Explanation
The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Balsm Alofoq Medical Co Altman Z2-Score Chart
Balsm Alofoq Medical Co Annual Data
Trend
Dec23
Dec24
Dec25
Altman Z2-Score
7.32
12.48
11.27
Balsm Alofoq Medical Co Semi-Annual Data
Dec23
Jun24
Dec24
Jun25
Dec25
Altman Z2-Score
7.32
0.00
12.48
0.00
11.27
SAU:9620 vs ABT, SYK, MDT: Altman Z2-Score Comparison
For the Medical Devices subindustry, Balsm Alofoq Medical Co's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Balsm Alofoq Medical Co Altman Z2-Score vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Balsm Alofoq Medical Co's Altman Z2-Score distribution charts can be found below:
* The bar in red indicates where Balsm Alofoq Medical Co's Altman Z2-Score falls into.
Balsm Alofoq Medical Co Altman Z2-Score Calculation
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.
Balsm Alofoq Medical Co (SAU:9620) has a Altman Z2-Score of 11.27 as of Aug. 06, 2026. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Balsm Alofoq Medical Co and its competitors. This is near median its historical median of 11.27. Over the past decade, Balsm Alofoq Medical Co's Altman Z2-Score has ranged from 7.32 to 12.48. According to the industry distribution chart, Balsm Alofoq Medical Co ranks #109 out of 841 companies in the Medical Devices & Instruments industry, placing it in the top 13%.
Is Balsm Alofoq Medical Co's Altman Z2-Score too high?
Balsm Alofoq Medical Co's current Altman Z2-Score of 11.27 is near median its 10-year median of 11.27. Over the past 10 years, this metric has ranged from a low of 7.32 to a high of 12.48. The Medical Devices & Instruments industry median Altman Z2-Score is 3.42. Balsm Alofoq Medical Co's value of 11.27 is 229.5% above this industry median. Based on the distribution chart, Balsm Alofoq Medical Co ranks #109 out of 841 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Balsm Alofoq Medical Co has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Balsm Alofoq Medical Co's Altman Z2-Score compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Balsm Alofoq Medical Co ranks #109 out of 841 companies for Altman Z2-Score. This places Balsm Alofoq Medical Co in the top 13% of its industry — outperforming the majority of peers. The industry median Altman Z2-Score is 3.42. Balsm Alofoq Medical Co's value of 11.27 is 229.5% above this benchmark. Historically, Balsm Alofoq Medical Co's own Altman Z2-Score has ranged from 7.32 to 12.48 over the past decade. While the company's 10-year median is 11.27 vs. the industry median of 3.42, Balsm Alofoq Medical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z2-Score for a Medical Devices & Instruments company?
The median Altman Z2-Score among Medical Devices & Instruments companies is 3.42, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z2-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z2-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Balsm Alofoq Medical Co's current Altman Z2-Score of 11.27 is 229.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z2-Score mean?
A high Altman Z2-Score can signal that a stock is expensive relative to its fundamentals. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Balsm Alofoq Medical Co and its competitors. For the Medical Devices & Instruments industry, the median Altman Z2-Score is 3.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Balsm Alofoq Medical Co's current Altman Z2-Score is 11.27, which is near median its own 10-year median of 11.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Balsm Alofoq Medical Co stock overvalued right now?
Balsm Alofoq Medical Co (SAU:9620) has a current Altman Z2-Score of 11.27. The current Altman Z2-Score is 11.27, which is near median its 10-year median of 11.27 and 229.5% above the Medical Devices & Instruments industry median of 3.42. Balsm Alofoq Medical Co's overall GF Score™ is 24/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z2-Score calculated?
Altman Z2-Score is calculated from a company's financial statements. For Balsm Alofoq Medical Co (SAU:9620), the current Altman Z2-Score is 11.27 as of Aug. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Balsm Alofoq Medical Co operates in the medical sector. Its activities include medical services, specialized clinics and medical complexes, medical operations, and the import and supply of medical devices and supplies to all regions of the Kingdom of Saudi Arabia.
24GF Score
Get the complete analysis for SAU:9620
Altman Z2-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SAU:9620 has been successfully added to your 
